Submucosal bevacizumab (DrugBank: Bevacizumab)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 227 | Osler disease | 3 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01314274 (ClinicalTrials.gov) | March 2011 | 9/3/2011 | Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) | A Randomized Double Blind Placebo Controlled Trial of Intranasal Submucosal Bevacizumab in Hereditary Hemorrhagic Telangiectasia | HHT;Morbus Osler;Epistaxis | Drug: Bevacizumab;Drug: NaCl | Medical University of Vienna | NULL | Completed | 18 Years | 80 Years | Both | 15 | Phase 2 | Austria |
| 2 | EUCTR2009-018049-19-AT (EUCTR) | 13/12/2010 | 23/11/2010 | A randomized double blind placebo controlled trial of intranasal submucosal bevacizumab in hereditary hemorrhagic telangiectasia - Bevazizumab in HHT | A randomized double blind placebo controlled trial of intranasal submucosal bevacizumab in hereditary hemorrhagic telangiectasia - Bevazizumab in HHT | epistaxis | Trade Name: AVASTIN 25 mg/ml - Konzentrat zur Herstellung einer Infusionsloesung INN or Proposed INN: BEVACIZUMAB Trade Name: PHYSIOLOGISCHE Kochsalzloesung Fresenius - Infusionsloesung Product Name: PHYSIOLOGISCHE Kochsalzloesung Fresenius - Infusionsloesung Other descriptive name: SODIUM CHLORIDE | Medizinische Universität Wien,Univ.Klinik f.Hals-, Nasen- und Ohrenkrankheiten | NULL | Not Recruiting | Female: yes Male: yes | 30 | Austria | |||
| 3 | NCT01402531 (ClinicalTrials.gov) | July 22, 2010 | 19/7/2011 | Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) | Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) | Hereditary Hemorrhagic Telangiectasia (HHT) | Drug: Submucosal Bevacizumab | University of California, San Diego | NULL | Completed | 18 Years | N/A | All | 10 | Phase 2 | United States |